glp 1 agonists for type 2 diabetes GLP-1 receptor are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Medscape | The use of
Description
A., A Prospective, ClaimsBased Assessment of the Risk of Pancreatitis and Pancreatic Cancer With Liraglutide Compared to Other Antidiabetic Drugs, Diabetes, Obesity & Metabolism 16 (2014): 273275
especially since the intrinsic hypoglycaemia risk of DPP-4 inhibitors is very low

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

Clin Obes

BAT, brown adipose tissue
